



Market Announcement

31 March 2023

Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt

Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 4 April 2023 or when the announcement is released to the market.

Issued by

Dale Wang

Adviser, Listings Compliance

ASX RELEASE

31 March 2023

By email: melissa.kostopoulos@asx.com.au

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne) ASX Limited

Dear Melissa

31 March 2023

Request for a trading halt

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

The Company has received biomarker, structural and clinical data relating to its phase 2 PARA_008 clinical trial. The Company is requesting a trading halt to analyse the data and prepare an ASX Announcement and investor webinar presentation on the data, to be released to the market on Tuesday 4 April 2023. Accordingly pursuant to ASX Listing Rule 17.1, the Company requests the trading halt in order to finalise its review and update to the market.

The Company requests that the trading halt remains in place until the earlier of the Company making an announcement in relation to the received PARA_008 data or commencement of trading on Tuesday 4 April 2023.

The Company is not aware of any reason why the trading halt should not be granted.

Authorised for release on behalf of the Board of Paradigm Biopharmaceuticals Limited.

Yours faithfully,



Abby Macnish Niven

Company Secretary